TELA Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
TELA$0.86+5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Assets · · · · | ||||||
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $50,845 | | $52,670 | ||
| Accounts receivable, net of allowances of $287 and $275 | | 10,347 | | 10,098 | ||
| Inventory | | 11,016 | | 12,781 | ||
| Prepaid expenses and other current assets | | 3,373 | | 2,522 | ||
| Total current assets | | 75,581 | | 78,071 | ||
| Property and equipment, net | | 2,226 | | 2,341 | ||
| Intangible assets, net | | 1,359 | | 1,739 | ||
| Right-of-use assets | | 1,502 | | 1,738 | ||
| Other long-term assets | | | 500 | | | 2,276 |
| Deferred tax asset, net | | | — | | | 140 |
| Restricted cash | | | 250 | | | 265 |
| Total assets | | $81,418 | | $86,570 | ||
| | | | | | | |
| Liabilities and stockholders’ equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $2,309 | | $2,147 | ||
| Accrued expenses and other current liabilities | | 15,666 | | 13,451 | ||
| Total current liabilities | | 17,975 | | 15,598 | ||
| Long‑term debt | | | 55,653 | | | 41,124 |
| Other long‑term liabilities | | 1,477 | | 1,390 | ||
| Total liabilities | | 75,105 | | 58,112 | ||
| | | | | | | |
| Commitments and contingencies (Note 12) | | | | | | |
| | | | | | | |
| Stockholders’ equity: | | | | | ||
| Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding | | | — | | | — |
| Common stock; $0.001 par value: 200,000,000 shares authorized; 44,538,264 and 39,395,712 shares issued and outstanding at December 31, 2025 and 2024, respectively | | 44 | | 39 | ||
| Additional paid-in capital | | | 403,739 | | | 387,059 |
| Accumulated other comprehensive income | | 91 | | 90 | ||
| Accumulated deficit | | (397,561) | | (358,730) | ||
| Total stockholders’ equity | | 6,313 | | 28,458 | ||
| Total liabilities and stockholders’ equity | | $81,418 | | $86,570 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.